Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.

In this study, we carried out phosphoproteomic analysis of lapatinib sensitive and resistant cell lines (SKBR3 and SKBR3-LR) using stable isotope labeling with amino acids in cell culture (SILAC). We identified 3808 phosphopeptides from 1807 proteins and then analyzed signaling pathways, Gene Ontology, and protein-protein interaction networks. Finally, we identified PAK2 as a therapeutic target from the network analysis and validated that PAK2 knockdown and PAK inhibitor treatment resensitize the lapatinib resistant cells to lapatinib. This results suggest that PAK2 is a potent therapeutic target to overcome acquired lapatinib resistance in HER2-positive breast cancer cells. PMID: 30243723 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30243723?dopt=Abstract

Source: Biochemical and Biophysical Research communications - September 19, 2018 Category: Biochemistry Authors: Chang Y, Park KH, Lee JE, Han KC Tags: Biochem Biophys Res Commun Source Type: research